Patents Assigned to Alnylam Pharmaceuticals, Inc.
  • Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
    Patent number: 11806360
    Abstract: Disclosed herein are methods for treating hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in a human patient in need thereof by administering an effective amount of a transthyretin (TTR)-inhibiting composition.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: November 7, 2023
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Jared Gollob
  • ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230340485
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting an anaplastic lymphoma kinase (ALK) gene, as well as methods of inhibiting expression of an ALK gene and methods of treating subjects having an ALK-associated disease or disorder, e.g., type 2 diabetes, obesity, or an obesity-associated disorder, using such dsRNAi agents and compositions.
    Type: Application
    Filed: June 15, 2021
    Publication date: October 26, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: BRET L. BOSTWICK, JAMES D. MCININCH
  • IRNA COMPOSITIONS AND METHODS FOR SILENCING GROWTH FACTOR RECEPTOR BOUND PROTEIN 10 (GRB10) OR GROWTH FACTOR RECEPTOR BOUND PROTEIN 14 (GRB14) IN THE LIVER
    Publication number: 20230332147
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the GRB 10 or GRB 14 gene, as well as methods of inhibiting expression of GRB 10 or GRB 14, and methods of treating subjects that would benefit from reduction in expression of GRB 10 or GRB 14, such as subjects having a GRB 10- or GRB 14-associated disease, disorder, or condition, such as diabetes, using such dsRNA compositions.
    Type: Application
    Filed: September 9, 2021
    Publication date: October 19, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: JAMES D. MCININCH, AIMEE DEATON, LUCAS BONDURANT, MARK K. SCHLEGEL, ADAM CASTORENO
  • TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230323357
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TRAF6 gene, as well as methods of inhibiting expression of TRAF6, and methods of treating subjects that would benefit from reduction in expression of TRAF6, such as subjects having a TRAF6-associated disease, disorder, or condition, using such dsRNA compositions.
    Type: Application
    Filed: June 8, 2021
    Publication date: October 12, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: ARLIN ROGERS, MELISSA MOBLEY, JAMES D. MCININCH
  • COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION
    Publication number: 20230295622
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting MYOC, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of MYOC.
    Type: Application
    Filed: April 6, 2021
    Publication date: September 21, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: MARK KEATING, JAMES D. MCININCH
  • G PROTEIN-COUPLED RECEPTOR 146 (GPR146) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230287432
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the G protein-coupled receptor 146 (GPR146). The invention also relates to methods of using such RNAi agents to inhibit expression of a GPR146 gene and to methods of preventing and treating a GPR146-associated disorders, e.g., hypercholesterolemia and atherosclerosis.
    Type: Application
    Filed: February 26, 2021
    Publication date: September 14, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: KEVIN FITZGERALD, FREDERIC TREMBLAY, JAMES D. MCININCH
  • MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT
    Publication number: 20230256001
    Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The antisense strand of the dsRNA molecule comprises at least one thermally destabilizing nucleotide occurring at a seed region; the dsRNA comprises at least four 2?-fluoro modifications, and the sense strand of the dsRNA molecule comprises ligand, wherein the ligand is an ASGPR ligand. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.
    Type: Application
    Filed: September 30, 2022
    Publication date: August 17, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Mark K. SCHLEGEL, Maja JANAS, Vasant R. JADHAV, Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, Muthusamy JAYARAMAN, Alexander V. KEL'IN, Shigeo MATSUDA, Klaus CHARISSE, Jayaprakash K. NAIR, Martin A. MAIER, Alfica SEHGAL, Christopher BROWN, Christopher THEILE, Stuart MILSTEIN
  • Serpina1 iRNA compositions and methods of use thereof
    Patent number: 11725207
    Abstract: The invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: August 15, 2023
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Mark K. Schlegel, Maja Janas, Vasant R. Jadhav, Donald Foster, Muthiah Manoharan, Kallanthottathil G. Rajeev, Alexander V. Kel'in, Klaus Charisse, Jayaprakash K. Nair, Martin A. Maier, Shigeo Matsuda, Muthusamy Jayaraman, Alfica Sehgal, Christopher Brown, Kevin Fitzgerald, Stuart Milstein
  • TMPRSS6 iRNA compositions and methods of use thereof
    Patent number: 11725209
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: August 15, 2023
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: James Butler, Martin A. Maier, Kevin Fitzgerald, Shannon Fishman, Donald Foster, Vasant R. Jadhav, Stuart Milstein
  • MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230203486
    Abstract: The disclosure relates to double stranded ribonucleic acid interference (dsRNAi) agents and compositions targeting a microtubule-associated protein tau (MAPT) gene, as well as methods of inhibiting expression of a MAPT gene and methods of treating subjects having a MAPT-associated disease or disorder, e.g., Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, or other tauopathies, using such dsRNAi agents and compositions.
    Type: Application
    Filed: March 30, 2021
    Publication date: June 29, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: MANGALA MEENAKSHI SOUNDARAPANDIAN, JAMES D. MCININCH, ELANE FISHILEVICH, ADAM CASTORENO, CHARALAMBOS KAITTANIS, MARK K. SCHLEGEL, JONATHAN EDWARD FARLEY, JEFFREY ZUBER
  • SIRNA COMPOSITIONS AND METHODS FOR SILENCING GPAM (GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1, MITOCHONDRIAL) EXPRESSION
    Publication number: 20230203496
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the GPAM gene, as well as methods of inhibiting expression of GPAM, and methods of treating subjects that would benefit from reduction in expression of GPAM, such as subjects having a GPAM-associated disease, disorder, or condition, using such dsRNA compositions.
    Type: Application
    Filed: June 9, 2021
    Publication date: June 29, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: JAMES D. MCININCH, LUCAS BONDURANT, AIMEE DEATON
  • Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
    Patent number: 11685918
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the programmed cell death 1 ligand 1 (PD-L1) gene, and methods of using such RNAi agents to inhibit expression of a PD-L1 gene and methods of treating subjects having a PD-L1-associated disorder.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: June 27, 2023
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Gregory Hinkle
  • COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION
    Publication number: 20230190785
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the DNAJC15 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of DNAJC15.
    Type: Application
    Filed: March 30, 2021
    Publication date: June 22, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: FREDERIC TREMBLAY, JAMES D. MCININCH
  • Biodegradable lipids for the delivery of active agents
    Patent number: 11679158
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: June 20, 2023
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • COMPOSITIONS AND METHODS FOR INHIBITING MARC1 GENE EXPRESSION
    Publication number: 20230183707
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the MARC1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of MARC1.
    Type: Application
    Filed: May 21, 2021
    Publication date: June 15, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: FREDERIC TREMBLAY, JAMES D. MCININCH
  • Carbohydrate conjugates as delivery agents for oligonucleotides
    Patent number: 11666653
    Abstract: The present invention provides a modified RNAi agent comprising a sense strand and an antisense strand, wherein the antisense strand targets an HBV mRNA; all of the nucleotide sugars of the RNAi agent are 2?-modified; and at least one of the sense and antisense strands is conjugated to at least one targeting ligand that comprises two or more building blocks connected to a biantennary or triantennary branched linker, optionally via one or more linking groups.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: June 6, 2023
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Nair, Martin Maier
  • COMPOSITIONS AND METHODS FOR SILENCING SCN9A EXPRESSION
    Publication number: 20230159933
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting SCN9A, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of SCN9A.
    Type: Application
    Filed: April 6, 2021
    Publication date: May 25, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: WILLIAM CANTLEY, JAMES D. MCININCH, ADAM CASTORENO, CHARALAMBOS KAITTANIS, MARK K. SCHLEGEL
  • Superoxide dismutase 1 (SOD1) iRNA compositions and methods of use thereof for treating or preventing superoxide dismutase 1-(SOD1-) associated neurodegenerative diseases
    Patent number: 11649459
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a SOD1 gene, as well as methods of inhibiting expression of a SOD1 gene and methods of treating subjects having a SOD1-associated neurodegenerative disease or disorder, e.g., Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), and Down's syndrome (DS), using such dsRNAi agents and compositions.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: May 16, 2023
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Adam Castoreno, Jason Gilbert, Charalambos Kaittanis, James D. McIninch, Stuart Milstein, Mark K. Schlegel
  • ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230138507
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting an alpha-2A adrenergic receptor (ADRA2A) gene, as well as methods of inhibiting expression of an ADRA2A gene and methods of treating subjects having an ADRA2A-associated disease or disorder, e.g., a primary tauopathy or Alzheimer's disease, using such dsRNAi agents and compositions.
    Type: Application
    Filed: April 1, 2021
    Publication date: May 4, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: BRET L. BOSTWICK, JAMES D. MCININCH, ADAM CASTORENO
  • COMPOSITIONS AND METHODS FOR SILENCING VEGF-A EXPRESSION
    Publication number: 20230136787
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting VEGF-A, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of VEGF-A.
    Type: Application
    Filed: February 9, 2021
    Publication date: May 4, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: JAMES D. MCININCH, MARK KEATING, MARK K. SCHLEGEL, ADAM CASTORENO, VASANT R. JADHAV, CHARALAMBOS KAITTANIS, ELENA CASTELLANOS-RIZALDOS, BHAUMIK A. PANDYA